Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7511.074 | 0.8900 | 0.8235 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7511.074 | 0.2005 | -0.4405 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7511.074 | 0.2005 | -0.4405 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7511.074 | 0.1035 | -0.6687 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7511.074 | 0.1035 | -0.6687 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7511.074 | 0.0885 | -0.7073 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7511.074 | 0.0885 | -0.7073 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7511.074 | 0.0442 | -0.8311 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 33.3 | uM | 7511.074 | 0.0442 | -0.8311 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7511.074 | 0.0394 | -0.8458 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 167 | uM | 7511.074 | 0.0394 | -0.8458 | 1.2617 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7512.074 | 0.9751 | 0.9448 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.000427 | uM | 7512.074 | 0.9751 | 0.9448 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7512.074 | 0.9117 | 0.8053 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.00213 | uM | 7512.074 | 0.9117 | 0.8053 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7512.074 | 0.9715 | 0.9370 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0107 | uM | 7512.074 | 0.9715 | 0.9370 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7512.074 | 0.9629 | 0.9180 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.0533 | uM | 7512.074 | 0.9629 | 0.9180 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7512.074 | 0.3820 | -0.3117 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 0.267 | uM | 7512.074 | 0.3820 | -0.3117 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7512.074 | 0.1800 | -0.7011 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 1.33 | uM | 7512.074 | 0.1800 | -0.7011 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7512.074 | 0.1344 | -0.7837 | 0.9022 | |
| MDA-MB-415 | HR+ | Luminal | Bortezomib | Proteasome | Proteasome | 6.67 | uM | 7512.074 | 0.1344 | -0.7837 | 0.9022 |